Tomas Hala

4.5k total citations · 1 hit paper
9 papers, 672 citations indexed

About

Tomas Hala is a scholar working on Pediatrics, Perinatology and Child Health, Rheumatology and Immunology. According to data from OpenAlex, Tomas Hala has authored 9 papers receiving a total of 672 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pediatrics, Perinatology and Child Health, 4 papers in Rheumatology and 4 papers in Immunology. Recurrent topics in Tomas Hala's work include Biosimilars and Bioanalytical Methods (4 papers), Pharmaceutical studies and practices (4 papers) and Rheumatoid Arthritis Research and Therapies (3 papers). Tomas Hala is often cited by papers focused on Biosimilars and Bioanalytical Methods (4 papers), Pharmaceutical studies and practices (4 papers) and Rheumatoid Arthritis Research and Therapies (3 papers). Tomas Hala collaborates with scholars based in United States, Czechia and United Kingdom. Tomas Hala's co-authors include Jae Bum Kim, Phillip D. Toth, Lesley Burgess, Eli M. Roth, Christie M. Ballantyne, Maria Laura Monsalvo, Evan A. Stein, Michael J. Koren, Robert C. Scott and Michael Lillestol and has published in prestigious journals such as New England Journal of Medicine, Annals of the Rheumatic Diseases and Arthritis Research & Therapy.

In The Last Decade

Tomas Hala

9 papers receiving 658 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia

2014 553 citations Dirk Blom, Tomas Hala et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tomas Hala United States	7	499	249	176	119	77	9	672
Kate Tsirtsonis United States	5	512 1.0×	227 0.9×	95 0.5×	128 1.1×	78 1.0×	6	618
Bei Wang China	8	515 1.0×	153 0.6×	95 0.5×	102 0.9×	67 0.9×	26	631
Marion Cousins Canada	10	497 1.0×	104 0.4×	75 0.4×	126 1.1×	116 1.5×	11	608
Roland P.T. Troquay Netherlands	5	568 1.1×	153 0.6×	107 0.6×	141 1.2×	148 1.9×	6	820
Shazia Ali United States	9	696 1.4×	122 0.5×	95 0.5×	353 3.0×	283 3.7×	37	1.0k
Nagwa Khilla United States	5	610 1.2×	110 0.4×	85 0.5×	314 2.6×	248 3.2×	11	849
Joost Besseling Netherlands	13	1.1k 2.2×	241 1.0×	64 0.4×	497 4.2×	382 5.0×	26	1.3k
D. Erlich France	12	411 0.8×	41 0.2×	39 0.2×	143 1.2×	122 1.6×	22	630
Thomas Hucko Germany	11	297 0.6×	71 0.3×	102 0.6×	52 0.4×	35 0.5×	19	548
Mary Elliott‐Davey United States	8	425 0.9×	128 0.5×	86 0.5×	125 1.1×	97 1.3×	8	514

Countries citing papers authored by Tomas Hala

Since Specialization

Citations

This map shows the geographic impact of Tomas Hala's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomas Hala with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomas Hala more than expected).

Fields of papers citing papers by Tomas Hala

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tomas Hala. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomas Hala. The network helps show where Tomas Hala may publish in the future.

Co-authorship network of co-authors of Tomas Hala

This figure shows the co-authorship network connecting the top 25 collaborators of Tomas Hala. A scholar is included among the top collaborators of Tomas Hala based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomas Hala. Tomas Hala is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Hala, Tomas, et al.. (2024). Tofacitinib Efficacy/Safety in Patients with Ankylosing Spondylitis by Baseline Body Mass Index: A Post Hoc Analysis of Phase 2/3 Trials. Rheumatology and Therapy. 12(1). 67–84. 1 indexed citations

2.

Genovese, Mark C., Juan Sánchez‐Bursón, Myungshin Oh, et al.. (2020). Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis. Arthritis Research & Therapy. 22(1). 60–60. 15 indexed citations

3.

Alten, Rieke, Bogdan Batko, Tomas Hala, et al.. (2019). Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54. RMD Open. 5(1). e000876–e000876. 19 indexed citations

4.

Cohen, Stanley, Rieke Alten, Hideto Kameda, et al.. (2018). A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy. Arthritis Research & Therapy. 20(1). 155–155. 45 indexed citations

5.

Alten, Rieke, Vira Tseluyko, Tomas Hala, et al.. (2018). FRI0137 Efficacy, safety and immunogenicity from week 30 to week 54 in a randomised, double-blind phase iii study comparing a proposed infliximab biosimilar (PF-06438179/GP1111) with reference infliximab. Annals of the Rheumatic Diseases. 77. 612–613. 3 indexed citations

6.

Blom, Dirk, Tomas Hala, Michael A. Bolognese, et al.. (2014). A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia. New England Journal of Medicine. 370(19). 1809–1819. 553 indexed citations breakdown →

7.

Blažková, Šárka, Vladimír Palička, J Štěpán, et al.. (2010). Osteoporosis risk assessment and management in primary care: focus on quantity and quality. Journal of Evaluation in Clinical Practice. 16(6). 1176–1182. 8 indexed citations

8.

Blažková, Šárka, et al.. (2008). Self-reported compliance with osteoporosis medication—Qualitative aspects and correlates. Maturitas. 60(3-4). 223–229. 11 indexed citations

9.

Kuběna, Aleš, et al.. (2006). Knowledge of osteoporosis correlated with hormone therapy use and health status. Maturitas. 56(1). 21–29. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact